Reduction in urinary excretion of neutrophil gelatinase-associated lipocalin by angiotensin receptor blockers in hypertensive patients.
Kasahara
Masato
M
Mori
Kiyoshi
K
Satoh
Noriko
N
Kuwabara
Takashige
T
Yokoi
Hideki
H
Shimatsu
Akira
A
Sugawara
Akira
A
Mukoyama
Masashi
M
Nakao
Kazuwa
K
D000209:Acute-Phase Proteins / Q000652:urine*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D057911:Angiotensin Receptor Antagonists; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000652:urine; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000652:urine; D007676:Kidney Failure, Chronic / Q000175:diagnosis*; D000071068:Lipocalin-2; D054834:Lipocalins / Q000652:urine*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy* / Q000652:urine; D011446:Prospective Studies; D011518:Proto-Oncogene Proteins / Q000652:urine*
D000209:Acute-Phase Proteins; D047228:Angiotensin II Type 1 Receptor Blockers; D057911:Angiotensin Receptor Antagonists; C489506:LCN2 protein, human; D000071068:Lipocalin-2; D054834:Lipocalins; D011518:Proto-Oncogene Proteins